» Articles » PMID: 26631721

Two Degradation Pathways of the P35 Cdk5 (Cyclin-dependent Kinase) Activation Subunit, Dependent and Independent of Ubiquitination

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2015 Dec 4
PMID 26631721
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Cdk5 is a versatile protein kinase that is involved in various neuronal activities, such as the migration of newborn neurons, neurite outgrowth, synaptic regulation, and neurodegenerative diseases. Cdk5 requires the p35 regulatory subunit for activation. Because Cdk5 is more abundantly expressed in neurons compared with p35, the p35 protein levels determine the kinase activity of Cdk5. p35 is a protein with a short half-life that is degraded by proteasomes. Although ubiquitination of p35 has been previously reported, the degradation mechanism of p35 is not yet known. Here, we intended to identify the ubiquitination site(s) in p35. Because p35 is myristoylated at the N-terminal glycine, the possible ubiquitination sites are the lysine residues in p35. We mutated all 23 Lys residues to Arg (p35 23R), but p35 23R was still rapidly degraded by proteasomes at a rate similar to wild-type p35. The degradation of p35 23R in primary neurons and the Cdk5 activation ability of p35 23R suggested the occurrence of ubiquitin-independent degradation of p35 in physiological conditions. We found that p35 has the amino acid sequence similar to the ubiquitin-independent degron in the NKX3.1 homeodomain transcription factor. An Ala mutation at Pro-247 in the degron-like sequence made p35 stable. These results suggest that p35 can be degraded by two degradation pathways: ubiquitin-dependent and ubiquitin-independent. The rapid degradation of p35 by two different methods would be a mechanism to suppress the production of p25, which overactivates Cdk5 to induce neuronal cell death.

Citing Articles

CDK5 Deficiency Does not Impair Neuronal Differentiation of Human Induced Pluripotent Stem Cells but Affects Neurite Outgrowth.

Mucci S, Clas G, Allio C, Rodriguez-Varela M, Isaja L, Marazita M Mol Neurobiol. 2024; 62(1):918-934.

PMID: 38937422 DOI: 10.1007/s12035-024-04325-y.


Targeted Protein Degradation: Principles and Applications of the Proteasome.

Kim Y, Kim E, Chey Y, Song M, Jang H Cells. 2023; 12(14).

PMID: 37508510 PMC: 10378610. DOI: 10.3390/cells12141846.


Ubiquitin ligase activity inhibits Cdk5 to control axon termination.

Desbois M, Opperman K, Amezquita J, Gaglio G, Crawley O, Grill B PLoS Genet. 2022; 18(4):e1010152.

PMID: 35421092 PMC: 9041834. DOI: 10.1371/journal.pgen.1010152.


Post-translational modifications of CDK5 and their biological roles in cancer.

Gao G, Sun Y, Fang R, Wang Y, Wang Y, He Q Mol Biomed. 2022; 2(1):22.

PMID: 35006426 PMC: 8607427. DOI: 10.1186/s43556-021-00029-0.


RPS23RG1 modulates tau phosphorylation and axon outgrowth through regulating p35 proteasomal degradation.

Zhao D, Zhou Y, Huo Y, Meng J, Xiao X, Han L Cell Death Differ. 2020; 28(1):337-348.

PMID: 32908202 PMC: 7853145. DOI: 10.1038/s41418-020-00620-y.


References
1.
Erales J, Coffino P . Ubiquitin-independent proteasomal degradation. Biochim Biophys Acta. 2013; 1843(1):216-21. PMC: 3770795. DOI: 10.1016/j.bbamcr.2013.05.008. View

2.
Rao V, Guan B, Mutton L, Bieberich C . Proline-mediated proteasomal degradation of the prostate-specific tumor suppressor NKX3.1. J Biol Chem. 2012; 287(43):36331-40. PMC: 3476300. DOI: 10.1074/jbc.M112.352823. View

3.
Shah K, Lahiri D . Cdk5 activity in the brain - multiple paths of regulation. J Cell Sci. 2014; 127(Pt 11):2391-400. PMC: 4038939. DOI: 10.1242/jcs.147553. View

4.
Malumbres M . Cyclin-dependent kinases. Genome Biol. 2014; 15(6):122. PMC: 4097832. DOI: 10.1186/gb4184. View

5.
Rei D, Mason X, Seo J, Graff J, Rudenko A, Wang J . Basolateral amygdala bidirectionally modulates stress-induced hippocampal learning and memory deficits through a p25/Cdk5-dependent pathway. Proc Natl Acad Sci U S A. 2015; 112(23):7291-6. PMC: 4466741. DOI: 10.1073/pnas.1415845112. View